Find out what scope of research is considered by our Biomedical research funding stream.
The scope of research to be considered by this funding stream includes:
- Research that predominantly utilises cellular, animals models of disease or post-mortem brain tissue. For instance, to investigate aetiology or potential therapeutics for dementia.
- Research that predominantly utilises genomic, proteomic or other 'omics' approaches.
- Research that seeks to discover or validate biomarkers in a research setting, including psychometric tests, to be utilised in diagnosis or monitoring of disease progression.
- Translational research that bridges between basic and clinical research.
- Early-stage clinical investigations of pharmacological agents, vitamins or other small molecule compounds for the delay, prevention or treatment of dementia or associated behavioural symptoms.
As a general guide, research that meets the following criteria would be considered by the Biomedical research funding stream:
Research that is relevant to dementia research, and would otherwise be within the remit of the usual calls of the BBSRC or MRC. An exception would be population sciences that would be considered by the Care, services and public health research funding stream.
Highlight notice 2018
We welcome research proposals across cause, cure, care and prevention of all forms of dementia through our biomedical and care, services and public health funding streams. However, we wish to highlight several areas where we would welcome more applications to our regular grant rounds in the hope of funding in these areas. These areas remain open to our 6-monthly call deadlines.
Real-world utility of biomarkers: There are a number of biological markers including amyloid-PET and other neuroimaging approaches, CSF analysis; genotyping, advanced neuropsychology and others that may add value and guide clinical decision making. We welcome research proposals that seek to address facilitators and barriers to their implementation in real-world settings, as well as provide information about to which patient groups these tests should be offered and when, or about their utility, efficacy and impact on diagnosis, cost, or social and ethical implications of being offered to patients.
Drug repurposing: We've supported a programme of drug discovery particularly focused on drugs repurposing since 2014. We would welcome both preclinical and clinical applications that include the identification and testing of repurposed drug possibilities. In addition we fund clinical trials of drug candidates with our US partner the Alzheimer’s Drug Discovery Foundation (ADDF) through cofounding in their PACT programme.
If you have any questions please contact us at [email protected]